-
Gastroenterology: The co-activation regulation of ZEB1 and YAP1 zinc dependence plays an important role in pancreatic cancer metastasis
Time of Update: 2021-01-23
In human pancreatic cancer cells, clinical samples, spontaneous mouse models (KPC and KPCZ), in-place xeno-transplant models, 3D spherical and organ-like models, the interaction between cancer-promoting zinc finger transporter ZIP4, zinc-dependent EMT transcription factor ZEB1, co-activation factor YAP1 and integrator alpha3 (ITGA3) was observed.
-
BMC Medicine: More than 300,000 people are at higher risk of death from drinking and not eating!
Time of Update: 2021-01-23
In the risk assessment of alcohol type and health, drinking spirits and beer/cider and mortality, significant cardiovascular events, cirrhosis and the risk of accident/self-harm increased significantly compared to drinking red wine.
-
To improve the access of innovative drugs for oncology and rare diseases, Takeda China and Magnesium Trust Health reached a strategic partnership
Time of Update: 2021-01-22
Focus on new special drugs, chronic drugs, rare drugs, equipment medical payment services magnesium letter health, at the signing ceremony Zhang Xiaodong President pointed out that magnesium letter will give full play to the experience of the field of innovative payment advantages, for Takeda's product development more access to innovative payment programs, and jointly help build a multi-level security system in the field of drug payment, so that high-quality medical resources benefit the people of the country.
-
J Hepatol: Telomerase, a new potential therapeutic target for liver stage!
Time of Update: 2021-01-22
anti-tumor activity of anti-TERT ASO is found in HCC cell line, and the use of antisant oligonucleotide chain silencing TRT is effective in cells with high proliferation and poor differentiation.
-
UNDER the COVID-19 pandemic: Virtual testing rises biotech company I...
Time of Update: 2021-01-21
COVID-19 has also changed clinical trials and virtual models have begun to emerge, a necessity for maintaining research and development activities in all disease areas during social isolation.
-
And platinum medicine CTLA-4 monoantigen HBM4003 initiated a Phase I clinical
Time of Update: 2021-01-21
On January 7, Insight database showed that CTLA-4 monoantibodies HBM4003 of Platinum Pharmaceuticals initiated a Phase I clinical trial for advanced solid tumors.
-
IDHwt diffuse low-level glioma molecular characteristics and prognosis correlation
Time of Update: 2021-01-21
Gliomas accounted for 0% (0/22), and the difference was significant (p 19 months in patients with IDHwtIII.
class glioma patients without GBM molecular characteristics had a medium OS of 57 months (p-0.2).
IDHwtII with GBM molecular characteristics is significantly different from OS in patients with class III.
-
Take stock of 23 breakthrough therapies by 2020 The most innovative pharmaceutical companies Traditional pharmaceutical companies only...
Time of Update: 2021-01-21
these products are from large international pharmaceutical companies such as Takeda, Novarlor, Pfizer, but also from Chinese companies such as Hengrui Pharmaceuticals, Kangfang Bio, Koji Bio, Wanchun Brin and other .01 Emerging innovative pharmaceutical companies: license in and CAR-T On July 10, three companies submitted applications, including Nanjing's legendary CAR-T therapy, which was the first to get the first breakthrough treatment drug identification from the China Drug Administration in August.
-
The first off-skin injection PD-L1! Corning Jerry/ Idea Dean Worley single anti-trump priority...
Time of Update: 2021-01-21
open label Phase II study evaluated the safety and anti-tumor activity of KN035 in patients with advanced MSI-H/dMMR cancer.
-
Year-end inventory: CAR-T cell weight study interpretation
Time of Update: 2021-01-21
In human clinical trials, scientists extracted T-cells from patients through a dialysis-like process and then genetically modified them in the lab to import the GENES that encode the CAR so that the T-cells could express the new subject.
-
Positive day clear TQC3721 declared clinically used for slow-blocking lungs and asthma
Time of Update: 2021-01-21
from the Insight database (), there are currently 2 main varieties of new class 1 drugs in the respiratory field under development, TQC3721 and TQC3564.
-
Sci Trans Med: New switch adjusts CAR-T cells...
Time of Update: 2021-01-21
scientists report in the journal Science Translational Medicine on the development of switchable CAR T cells that can be turned on or off by giving commonly used cancer drugs.
source: Scientists create ON-OFF switches to control CAR T cell activity Source: M.
-
3 years 27 Hong Kong stocks BioTech why Hansen, Baiji and Thyda killed heavy...
Time of Update: 2021-01-21
Hansen Pharmaceuticals specialty psycho-drugs in China accounted for the first imitation combination, a number of products listed net profit of up to 30% Hansen Pharmaceuticals was established at the end of 2015, only the main body of overseas listing, its main business is Jiangsu Howson Pharmaceuticals, founded in 1995, headquartered in Lianyungang, mainly engaged in generic drugs (first generic drugs-based) and innovative drug research and development, production and sales.
-
End-of-2020 inventory: Science Magazine's breakthrough research!
Time of Update: 2021-01-21
doi:10.1126/science.aaz3834 Noncommunicable diseases, including heart disease, cancer and lung disease, are common causes of death among the population, accounting for 70 per cent of global deaths and are considered non-communicable because of a number of factors In a recent study published in the international journal Science, researchers from the University of British Columbia and other institutions found that many diseases may be spread among people through microbes living in our bodies, including bacteria, fungi and viruses.
-
Roche's Tiragolumab receives breakthrough drug funding...
Time of Update: 2021-01-21
Roche recently announced that the U.S. Food and Drug Administration (FDA) has awarded TIGIT target new cancer immunotherapy Tiragolumab Breakthrough Drug Qualification (BTD), a combination of anti-PD-L1 therapy Tecentriq (Tai Santqi, Common name: atezolizumab, atiliju single anti), first-line treatment of tumors showing PD-L1 high expression, no EGFR or ALC genome tumor distortion metastasis non-small cell lung cancer (NSCLC) patients.
-
End of 2020: Cancer immunotherapy's heavyweight research findings read!
Time of Update: 2021-01-21
The reprogramming process involves a new method developed by researchers that inhibits the activity of a protein called MEK1/2, which is currently used to effectively treat melanoma, but this study shows that MEK inhibitors do not target specific types of cancer cells, but can widely reprogram T cells to look for multiple types of cancer.
-
Innovation says Wang Pharmaceuticals is laying off workers... 2021 These pharmaceutical policies still need to be noted!
Time of Update: 2021-01-21
With the experience of drug national harvesting, after the national multi-site pilot on the basis of this year's high-value supplies country picked the first shot, the first single aim has been the leading role of clinical abuse has been repeatedly banned - coronary stent, that is, heart stent, stent product circulation in the price of water, industry insiders said that through collection can play a role in reducing prices, saving health insurance funds.
-
EGFR is a key link in GBM's sensitivity to dopamine-like inhibitors
Time of Update: 2021-01-20
studies have shown that receptor tyrosine kinase (RTK) and epidermal growth factor receptors (epidermal growth factor receptors, EGFR) often amplification or mutation in GBM; Yuyu He of the University of Minnesota, USA, and others analyzed the expression patterns of DRD2 and EGFR using the Cancer Genome Atlas (TCGA) GBM database and related literature; study Methods Numerous studies have supported the use of DRD2 inhibitors in the treatment of GBM, but not all GBM patients are effective.
-
JEM: New combination strategies may be expected to enhance the effectiveness of breast cancer immunotherapy!
Time of Update: 2021-01-20
In the study, researcher Serody and colleagues tested a variety of strategies in breast cancer mouse models to enhance the effectiveness of CAR-T cells, one of which was to use drugs such as cGAMP to treat mice that were able to activate STING paths in their bodies, an immune cell signaling pathline that normally induces inflammation of the body to respond to invading viruses or bacteria.
-
Nat Immunol: Key proteins are involved in T-cell metabolism and anti-tumor immune response
Time of Update: 2021-01-20
January 5, 2021 // -- Researchers at the University of Texas MD Anderson Cancer Center have found that a protein called NF-B-induced kinase (NIK) is critical to changes in metabolic activity caused by T-cell activation, making it a key factor in regulating T-cell anti-tumor activity.
